TCT 575: Post Market Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24 Month Clinical Outcomes in First 100 Patients

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; REVA Medical; AstraZenca; CardiacDimensions